Delcath Systems, Inc. Profile Avatar - Palmy Investing

Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery s…

Medical - Specialties
US, New York [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of DCTH's Analysis
CIK: 872912 CUSIP: 24661P807 ISIN: US24661P8077 LEI: - UEI: -
Secondary Listings
DCTH has no secondary listings inside our databases.